Lactobacillus sp. strain having ability to inhibit proliferation of virginal pathogenic microorganisms

Abstract

The present invention relates to a novel Lactobacillus sp. isolation strain having an activity to inhibit the growth of vaginitis pathogens, and a pharmaceutical composition, a health functional food, and a cleansing product, comprising the strain as an active ingredient. Therefore, the present invention exhibits an effect of inhibiting the growth of Sneathia spp. pathogens associated with the infection with human papillomavirus (HPV) and the incidence of bacterial vaginitis, Gardnerella vaginalis as a vaginitis pathogen, and Candida albicans as a causative bacteria of Candidal vaginitis, and an effect of recovering and maintaining the vaginal microflora, and thus can be used for the prevention and treatment of female vaginitis.

1 . A  Lactobacillus  sp. strain having an activity to inhibit the growth of pathogenic vaginal microorganisms. 
     
     
         2 . The  Lactobacillus  sp. strain of  claim 1 , wherein the pathogenic vaginal microorganism is at least one selected from the group consisting of fungi, bacteria and viruses. 
     
     
         3 . The  Lactobacillus  sp. strain of  claim 2 , wherein the pathogenic vaginal microorganism is at least one selected from the group consisting of a  Candida  sp. strain, a  Sneathia  spp. strain, a  Gardnerella  sp. strain, and human papillomavirus. 
     
     
         4 . The  Lactobacillus  sp. strain of  claim 3 , wherein the  Sneathia  spp. strain is  Sneathia amnii  or  Sneathia sanguinegens , or the  Candida  sp. strain is  Candida albicans , or the  Gardnerella  sp. strain is  Gardnerella vaginalis.    
     
     
         5 . (canceled) 
     
     
         6 . The  Lactobacillus  sp. strain of  claim 1 , wherein the  Lactobacillus  sp. strain is at least one selected from the group consisting of  Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus jensenii , and  Lactobacillus gasseri.    
     
     
         7 . The  Lactobacillus  sp. strain of  claim 1 , wherein the  Lactobacillus  sp. strain is at least one selected from the group consisting of  Lactobacillus crispatus  SNUV 220 deposited under accession No. KCTC18374P,  Lactobacillus fermentum  SNUV 175 deposited under accession No. KCTC18371P,  Lactobacillus jensenii  SNUV 360 deposited under accession No. KCTC18372P, and  Lactobacillus gasseri  SNUV 281 deposited under accession No. KCTC18375P. 
     
     
         8 . The  Lactobacillus  sp. strain of  claim 1 , wherein the  Lactobacillus  sp. strain has a survival rate of 50% or higher at a concentration of 0.1% (w/v) bile salt. 
     
     
         9 . A pharmaceutical composition for treating or preventing vaginitis comprising, as an active ingredient, the  Lactobacillus  sp. strain having an activity to inhibit the growth of pathogenic vaginal microorganisms according to  claim 1 . 
     
     
         10 . The pharmaceutical composition for treating or preventing vaginitis of  claim 9 , wherein the pathogenic vaginal microorganism is at least one selected from the group consisting of a  Candida  sp. strain, a  Sneathia  spp. strain, a  Gardnerella  sp. strain, and human papillomavirus. 
     
     
         11 . The pharmaceutical composition for treating or preventing vaginitis of  claim 10 , wherein the  Sneathia  spp. strain is  Sneathia amnii  and  Sneathia sanguinegens , or the  Candida  sp. strain is  Candida albicans , or the  Gardnerella  sp. strain is  Gardnerella vaginalis.    
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . A health functional food for improving, treating or preventing vaginitis comprising, as an active ingredient, the  Lactobacillus  sp. strain having an activity to inhibit the growth of pathogenic vaginal microorganisms according to  claim 1 . 
     
     
         15 . The health functional food for improving, treating or preventing vaginitis of  claim 14 , wherein the pathogenic vaginal microorganism is at least one selected from the group consisting of a  Candida  sp. strain, a  Sneathia  spp. strain, a  Gardnerella  sp. strain, and human papillomavirus. 
     
     
         16 . The health functional food for improving, treating or preventing vaginitis of  claim 15 , wherein the  Sneathia  spp. strain is  Sneathia amnii  and  Sneathia sanguinegens  or the  Candida  sp. strain is  Candida albicans , or the  Gardnerella  sp. strain is  Gardnerella vaginalis.    
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . The health functional food for improving, treating or preventing vaginitis of  claim 14 , wherein the health functional food is a beverage, a fermented milk, or a food additive. 
     
     
         20 . A cleansing product for improving, treating or preventing vaginitis comprising, as an active ingredient, the  Lactobacillus  sp. strain having an activity to inhibit the growth of pathogenic vaginal microorganisms according to  claim 1 . 
     
     
         21 . The cleansing product for improving, treating or preventing vaginitis of  claim 20 , wherein the pathogenic vaginal microorganism is at least one selected from the group consisting of a  Candida  sp. strain, a  Sneathia  spp. strain, a  Gardnerella  sp. strain, and human papillomavirus. 
     
     
         22 . The cleansing product for improving, treating or preventing vaginitis of  claim 21 , wherein the  Sneathia  spp. strain is  Sneathia amnii  and  Sneathia sanguinegens.    
     
     
         23 . (canceled) 
     
     
         24 . The cleansing product for improving, treating or preventing vaginitis of  claim 21 , wherein the  Candida  sp. strain is  Candida albicans , and the  Gardnerella  sp. strain is  Gardnerella vaginalis.    
     
     
         25 . The cleansing product for improving, treating or preventing vaginitis of  claim 20 , wherein the cleansing product is a solid cosmetic soap, a hand cleaner, a liquid shampoo, a liquid soap, a liquid conditioner, a body cleanser, or a creamy soap.